GRO beta

N/A

Report date: 2024/03/26 20:00:33
NME

Base Information

Drug NameGRO beta
Drug Alias NameGroβTMGTA-145
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionC-X-C motif chemokine receptor 2 agonists
TargetsC-X-C motif chemokine receptor 2
Therapy Area/IndicationsMyelodysplastic SyndromesAnemia, Sickle CellMultiple Myeloma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMagenta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesStanford University School of Medicine
Inactive CompaniesEnsoma Inc
Active IndicationsMultiple Myeloma
Inactive IndicationsMyelodysplastic SyndromesAnemia, Sickle CellLeukemia, Myeloid, Acute +[4] 

Other Information

ATC CodeN/A
Related LinksN/A